Article Text

Download PDFPDF
Short course nevirapine was better than zidovudine for reducing the risk of mother to child transmission of HIV-1 infection

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In pregnant women with HIV-1 infection, is short course nevirapine more effective than a short zidovudine regimen for reducing the risk of mother to child transmission of HIV-1 infection?


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:


Embedded ImageFollow up period:

6–8 weeks, 14–16 weeks, and 18 months.

Embedded ImageSetting:

{Mulago hospital in Kampala, Uganda}.

Embedded ImagePatients:

626 women who were {⩾18 years of age (mean age 24.5 y) at >32 weeks gestation, tested HIV-1 positive, and lived near the study site. Exclusion criteria included current antiretroviral or HIV-1 immunotherapy, uncontrolled hypertension, haemoglobin concentration <75 g/l, blood creatinine concentration >1.5 mg/dl, blood alanine aminotransferase concentration >3 times the upper limit of normal, and chronic alcohol or illicit drug use.}

Embedded ImageInterventions:

Of the 313 mothers who were allocated to a 200 mg nevirapine tablet at the onset of labour, …

View Full Text


  • * See glossary.

  • For correspondence: Dr J B Jackson, Johns Hopkins School of Medicine, Baltimore, MD, USA.

  • Source of funding: HIVNET; NIAID; NIH; DHHS and HPTN.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd